Tomislav Pejcic

Prof. Tomislav Pejcic


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
TPTomislav Pejcic
Tomislav Pejcic
Milica ZekovicMilica Zekovic
Milica Zekovic
Uros BumbasirevicUros Bumbasirevic
Uros Bumbasirevic
MKMilica Kalaba
Milica Kalaba
IVIrena Vovk
Irena Vovk
Živoslav Lj TešićŽivoslav Lj Tešić
Živoslav Lj Tešić
This narrative review summarizes epidemiological studies on breast cancer and prostate cancer with an overview of their global incidence distribution to investigate the relationship between these diseases and diet. The biological properties, mechanisms of action, and available data supporting the potential role of isoflavones in the prevention of breast cancer and prostate cancer are discussed. Studies evaluating the effects of isoflavones in tissue cultures of normal and malignant breast and prostate cells, as well as the current body of research regarding the effects of isoflavones attained through multiple modifications of cellular molecular signaling pathways and control of oxidative stress, are summarized. Furthermore, this review compiles literature sources reporting on the following: (1) levels of estrogen in breast and prostate tissue; (2) levels of isoflavones in the normal and malignant tissue of these organs in European and Asian populations; (3) average concentrations of isoflavones in the secretion of these organs (milk and semen). Finally, particular emphasis is placed on studies investigating the effect of isoflavones on tissues via estrogen receptors (ER).

8 June 2017 in The Prostate
Verified
Journal Article
Closed access
PDF file
TPTomislav Pejcic
Tomislav Pejcic
Tomislav TostiTomislav Tosti
Tomislav Tosti
ŽTŽivoslav Tešić
Živoslav Tešić
BMBorivoj Milković
Borivoj Milković
DDDejan Dragičević
Dejan Dragičević
ZDZoran Džamić
Zoran Džamić

Verified
Journal Article
Open access
PDF file
Milica ZekovicMilica Zekovic
Milica Zekovic
Uros BumbasirevicUros Bumbasirevic
Uros Bumbasirevic
MZMarko Zivkovic
Marko Zivkovic
TPTomislav Pejcic
Tomislav Pejcic
Cancer is increasingly recognized as an extraordinarily heterogeneous disease featuring an intricate mutational landscape and vast intra- and intertumor variability on both genetic and phenotypic levels. Prostate cancer (PCa) is the second most prevalent malignant disease among men worldwide. A single metabolic program cannot epitomize the perplexing reprogramming of tumor metabolism needed to sustain the stemness of neoplastic cells and their prominent energy-consuming functional properties, such as intensive proliferation, uncontrolled growth, migration, and invasion. In cancerous tissue, lipids provide the structural integrity of biological membranes, supply energy, influence the regulation of redox homeostasis, contribute to plasticity, angiogenesis and microenvironment reshaping, mediate the modulation of the inflammatory response, and operate as signaling messengers, i.e., lipid mediators affecting myriad processes relevant for the development of the neoplasia. Comprehensive elucidation of the lipid metabolism alterations in PCa, the underlying regulatory mechanisms, and their implications in tumorigenesis and the progression of the disease are gaining growing research interest in the contemporary urologic oncology. Delineation of the unique metabolic signature of the PCa featuring major aberrant pathways including de novo lipogenesis, lipid uptake, storage and compositional reprogramming may provide novel, exciting, and promising avenues for improving diagnosis, risk stratification, and clinical management of such a complex and heterogeneous pathology.

23 July 2007 in BJU International
Verified
Journal Article
Closed access
PDF file
JHJovan B. Hadzi‐Djokic
Jovan B. Hadzi‐Djokic
TPTomislav Pejcic
Tomislav Pejcic
VCVidosav C. Colovic
Vidosav C. Colovic

23 June 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
Uroš M GašićUroš M Gašić
Uroš M Gašić
Ivanka ĆirićIvanka Ćirić
Ivanka Ćirić
TPTomislav Pejcic
Tomislav Pejcic
DRDejan Radenkovic
Dejan Radenkovic
VDVladimir Djordjević
Vladimir Djordjević
Živoslav Lj TešićŽivoslav Lj Tešić
Živoslav Lj Tešić
Pancreatic cancer (PC) is very aggressive and it is estimated that it kills nearly 50% of patients within the first six months. The lack of symptoms specific to this disease prevents early diagnosis and treatment. Today, gemcitabine alone or in combination with other cytostatic agents such as cisplatin (Cis), 5-fluorouracil (5-FU), irinotecan, capecitabine, or oxaliplatin (Oxa) is used in conventional therapy. Outgoing literature provides data on the use of polyphenols, biologically active compounds, in the treatment of pancreatic cancer and the prevention of acute pancreatitis. Therefore, the first part of this review gives a brief overview of the state of pancreatic disease as well as the procedures for its treatment. The second part provides a detailed overview of the research regarding the anticancer effects of both pure polyphenols and their plant extracts. The results regarding the antiproliferative, antimetastatic, as well as inhibitory effects of polyphenols against PC cell lines as well as the prevention of acute pancreatitis are presented in detail. Finally, particular emphasis is given to the polyphenolic profiles of apples, berries, cherries, sour cherries, and grapes, given the fact that these fruits are rich in polyphenols and anthocyanins. Polyphenolic profiles, the content of individual polyphenols, and their relationships are discussed. Based on this, significant data can be obtained regarding the amount of fruit that should be consumed daily to achieve a therapeutic effect.

23 September 2008 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
JHJovan Hadzi-Djokic
Jovan Hadzi-Djokic
TPTomislav Pejcic
Tomislav Pejcic
MAMiodrag Acimovic
Miodrag Acimovic